Liquid Biopsy Clinical Research – Looking at Tumor Evolution with cfDNA

Today, clinical researchers are using automated, end-to-end solutions to make the most of limited liquid biopsy samples. To enable this work, leaders in the field are partnering with us to design next-generation sequencing (NGS) assays that target critical questions in cancer research and tumor biology.

Professor José Luis Costa, PhD, i3S/IPATIMUP, is leading efforts to use cell-free DNA (cfDNA) to detect rare mutations in lung cancer research blood samples. After his workshop at the Association of Molecular Pathology, we talked with him about the liquid biopsy applications.

Prof Jose Luis CostaHis preliminary data (right) shows concordance in detection of somatic variants on cfDNA lung cancer research samples using the Ion™ AmpliSeq Colon and Lung Cancer Research Panel v2 and analyses on the Ion™ PGM System and the Applied Biosystems™ QuantStudio™ 3D Digital PCR System.

 

For more information on Liquid biopsy solutions and upcoming 2016 conferences click here.

 

For Research Use Only. Not for use in diagnostic procedures.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get news and research reviews on the topic of your choice, right in your inbox.

Subscribe Now

  • This field is for validation purposes and should be left unchanged.